Ppd testing in patients starting infliximab for treatment of inflammatory bowel disease

被引：0
|
作者：
Minor, Melissa
Ghimire, Sanjay
Singh, Surya
机构：
[1] Brigham & Womens Hosp, Boston, MA 02115 USA
[2] D2Hawkeye Inc, Waltham, MA USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2008年 / 103卷
关键词：
D O I：
10.14309/00000434-200809001-01042
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1042
引用
收藏
页码：S408 / S408
页数：1
相关论文
共 50 条
  • [41] Infliximab: Use in inflammatory bowel disease
    Travassos W.J.
    Cheifetz A.S.
    Current Treatment Options in Gastroenterology, 2005, 8 (3) : 187 - 196
  • [42] Infliximab/RisankizumabPulmonary inflammatory bowel disease
    Reactions Weekly, 2024, 1996 (1) : 118 - 118
  • [43] The Effect of Infliximab and Adalimumab Treatment on Angiogenic Factor Levels in Patients With Inflammatory Bowel Disease (IBD)
    Algaba, Alicia
    Linares, Pablo M.
    Contreras, Maria Encarnacion Fernandez
    Figuerola, Ariadna
    Calvet, Xavier
    Guerra, Ivan
    Villa, Jose Carlos
    Chaparro, Maria
    Agullo, Jose Luis Rodriguez
    Gisbert, Javier P.
    Bermejo, Fernando
    GASTROENTEROLOGY, 2012, 142 (05) : S869 - S870
  • [44] Therapeutic thresholds for infliximab trough levels during maintenance treatment in patients with inflammatory bowel disease
    Rasmussen, M.
    Brynskov, J.
    Ainsworth, M. A.
    Buhl, S.
    Bendtzen, K.
    Steenholdt, C.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S409 - S409
  • [45] Dosing interval and diagnosis predict infliximab levels in patients with inflammatory bowel disease on maintenance treatment
    Krajcovicova, A.
    Batovsky, M.
    Gregus, M.
    Hlista, M.
    Durina, J.
    Leskova, Z.
    Sturdik, I
    Gojdic, M.
    Jalali, Y.
    Koller, T.
    Toth, J.
    Huorka, M.
    Hlavaty, T.
    ACTA GASTRO-ENTEROLOGICA BELGICA, 2018, 81 (04) : 465 - 470
  • [46] Evaluation of the efficacy and safety of the use of subcutaneous infliximab in the treatment of inflammatory bowel disease in naive patients
    Escobar, J.
    Perez, J.
    Plaza, R.
    Castillo, M.
    Saez, O.
    Ponferrada, A.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1454 - I1456
  • [47] Outcomes After Primary Infliximab Treatment Failure in Inflammatory Bowel Disease
    Buhl, Sine
    Steenholdt, Casper
    Rasmussen, Maria
    Borghede, Marta K.
    Brynskov, Jorn
    Thomsen, Ole O.
    Ainsworth, Mark A.
    INFLAMMATORY BOWEL DISEASES, 2017, 23 (07) : 1210 - 1217
  • [48] Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease
    Siegel, CoreyA.
    Levy, L. Campbell
    Mackenzie, Todd A.
    Sands, Bruce E.
    INFLAMMATORY BOWEL DISEASES, 2008, 14 (01) : 1 - 6
  • [49] Intentional treatment with infliximab during pregnancy in women with inflammatory bowel disease
    Schnitzler, Fabian
    Fickler, Herma H.
    Ferrante, Marc
    Noman, Maja
    Van assche, Gert A.
    Spitz, Bernard
    Vermeire, Severine
    Rutgeerts, Paul J.
    GASTROENTEROLOGY, 2007, 132 (04) : A144 - A144
  • [50] Variation in Infliximab Administration Practices in the Treatment of Pediatric Inflammatory Bowel Disease
    Adler, Jeremy
    Sandberg, Kelly C.
    Shpeen, Benjamin H.
    Eder, Sally J.
    Dhanani, Muhammad
    Clark, Sarah J.
    Freed, Gary L.
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2013, 57 (01): : 35 - 38
12345